Hypophysitis is a typical endocrine side effect of anti-CTLA-4 agents, since as hypothesized in some studies, CTLA-4 is expressed in prolactin (PRL) and TSH-secreting pituitary cells. Here, CTLA4 is linked to hypophysitis.